FMP
Anthera Pharmaceuticals, Inc.
ANTH
PNK
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
0.0001 USD
0 (0%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. John Craig Thompson
sector
Healthcare
industry
Biotechnology
website
https://www.anthera.comexchange
PNK
Description
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
CIK
0001316175
ISIN
US03674U3005
CUSIP
03674U300
Address
The Pennzoil Building
Phone
410 350 1839
Country
US
Employee
21
IPO Date
Mar 1, 2010
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ANTH Financial Summary
CIK
0001316175
Exchange
PNK
Industry
Biotechnology
Sector
Healthcare
CUSIP
03674U300
ISIN
US03674U3005
Country
US
Price
0
Beta
-123.12
Volume Avg.
3.99k
Market Cap
26
Shares
-
52-Week
1.0E-4-2.0E-4
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.01
P/B
-
Website
https://www.anthera.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ANTH News
It looks like there's no news available.
